#ketaminetherapy

Psychedelic InstitutePsychedelicInstitute
2025-10-10

psychedelicmentalhealth.net/re Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)
"Findings suggested that racemic ketamine (including by mouth), when appropriately dosed and administered within a structured clinical and safety monitoring framework, is both effective, safe and well-tolerated over a 6-month treatment period."

Psychedelic InstitutePsychedelicInstitute
2025-10-01

psychedelicmentalhealth.net/sp Spotlight: Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study (Beaglehole, et al, 2025)
"We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD."

Psychedelic InstitutePsychedelicInstitute
2025-09-30

Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)
" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. " psychedelicmentalhealth.net/ef

Psychedelic InstitutePsychedelicInstitute
2025-09-26

Spotlight: First study to compare two ketamine therapies for patients with severe depression
IV ketamine found to offer faster response with greater improvements than FDA-approved intranasal esketamine (Spravato) psychedelicmentalhealth.net/iv

Psychedelic InstitutePsychedelicInstitute
2025-09-24

psychedelicmentalhealth.net/co Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review (Meisner, et al, 2025) "treatment with IV racemic ketamine was associated with a more rapid response and greater overall efficacy than treatment with IN esketamine."

Psychedelic InstitutePsychedelicInstitute
2025-09-22

psychedelicmentalhealth.net/sp Spotlight: Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review (Thomas, et al, 2025)
"...ketamine has been tested in nine RBCTs targeting cocaine, alcohol, opioid use disorder, and nicotine, suggesting efficacy for addiction in combination with psychotherapies, and often when doses produce subjectively reported mystical or psychedelic experiences."

Psychedelic InstitutePsychedelicInstitute
2025-09-20

psychedelicmentalhealth.net/ke Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025) "patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits. "

Psychedelic InstitutePsychedelicInstitute
2025-09-19

psychedelicmentalhealth.net/ps Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025) "These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."

Psychedelic InstitutePsychedelicInstitute
2025-09-16

psychedelicmentalhealth.net/in Spotlight: Intravenous Ketamine Followed by Intranasal Esketamine in 2 Subsequent Treatment-resistant Depressive Episodes: Insights From a Case Series (Carminati, et al, 2025)
"Findings from this case series suggest that both and esketamine are associated with significant reductions in depressive symptoms in TRD. We observed a generally better response to ketamine than to esketamine."

Psychedelic InstitutePsychedelicInstitute
2025-09-12

Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder. Ketamine-assisted psychotherapy (KAP) is part of an emerging model of psychedelic medicine that employs psychoactive agents to support the psychotherapeutic process. psychedelicmentalhealth.net/sp

Addiction Rehab Clinics Ltdaddictionrehabclinics
2025-09-11

Addiction Rehab Clinics is currently experiencing technical issues with our ketamine therapy cost information page. We apologise for any inconvenience and are working diligently to restore full access. If you need immediate information about ketamine therapy costs or treatment options, please reach out to our team directly. addictionrehabclinics.co.uk/ke

Psychedelic InstitutePsychedelicInstitute
2025-09-09

psychedelicmentalhealth.net/sp Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)
"...the real-world clinical data presented here suggest a sustained effectiveness and safety profile of longer-term ketamine treatment for up to 6 months for patients with TRD. "

Psychedelic InstitutePsychedelicInstitute
2025-09-05

psychedelicmentalhealth.net/sp Spotlight- From Anesthetic to Neuroprotector: Multi-Omics Reveals Ketamine's Previously Unexplored Neuroprotective Role in Alzheimer's Disease (Gong, et al, 2025) This integrative study identifies robust diagnostic biomarkers and nominates ketamine for repurposing in AD. Experimental validation of ketamine's neuroprotective effects and FIBP's role is warranted.

Psychedelic InstitutePsychedelicInstitute
2025-09-04

pubmed.ncbi.nlm.nih.gov/409011 Optimizing ketamine dosing strategies across diverse clinical applications: a comprehensive review (Kedwany, et al, 2025)

Psychedelic InstitutePsychedelicInstitute
2025-08-29

Is a ? psychedelicmentalhealth.net/is

Did you know ketamine was coined a "dissociative anesthetic" by the wife of the chemist who first synthesized it lest its potential use in medicine be ruined due to its association with "classical psychedelics"?

Psychedelic InstitutePsychedelicInstitute
2025-08-27

psychedelicmentalhealth.net/ke Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025) "Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."

Client Info

Server: https://mastodon.social
Version: 2025.07
Repository: https://github.com/cyevgeniy/lmst